Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Total Valuation
Cogent Biosciences has a market cap or net worth of $507.77M. The enterprise value is $702.59M.
Market Cap$507.77M
Enterprise Value$702.59M
Share Statistics
Cogent Biosciences has 113.85M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113.85M
Owened by Insiders11.78%
Owened by Instutions0.68%
Financial Efficiency
Cogent Biosciences’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is -100.80%.
Return on Equity (ROE)-99.83%
Return on Assets (ROA)-78.03%
Return on Invested Capital (ROIC)-100.80%
Return on Capital Employed (ROCE)-101.38%
Revenue Per Employee$0
Profits Per Employee-$1,248,092.683
Employee Count205
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cogent Biosciences is -2.24. Cogent Biosciences’s PEG ratio is -0.05.
PE Ratio-2.24
PS Ratio0.00
PB Ratio2.23
Price to Fair Value2.23
Price to FCF-2.75
Price to Operating Cash Flow-2.75
PEG Ratio-0.05
Income Statement
In the last 12 months, Cogent Biosciences had revenue of $0.00 and earned -$255.86M in profits. Earnings per share was -$2.46.
Revenue$0.00
Gross Profit-$2.15M
Operating Income-$275.94M
Pretax Income-$255.86M
Net Income-$255.86M
EBITDA-272.06M
Earnings Per Share (EPS)-2.46
Cash Flow
In the last 12 months, operating cash flow was -$207.79M and capital expenditures -$573.00K, giving a free cash flow of -$208.36M billion.
Operating Cash Flow-$207.79M
Free Cash Flow-$208.36M
Free Cash Flow per Share-$1.83
Dividends & Yields
Cogent Biosciences pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-36.32%
Earnings Yield-44.72%
Stock Price Statistics
Beta0.99
52-Week Price Change-38.25%
50-Day Moving Average7.23
200-Day Moving Average9.02
Relative Strength Index (RSI)31.36
Average Volume (3m)1.40M
Important Dates
Cogent Biosciences upcoming earnings date is May 13, 2025, TBA.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Cogent Biosciences as a current ratio of 5.32, with Debt / Equity ratio of 0.07
Current Ratio5.32
Quick Ratio5.32
Debt to Market Cap0.03
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cogent Biosciences has paid -$4.06M in taxes.
Income Tax-$4.06M
Effective Tax Rate0.00%
Enterprise Valuation
Cogent Biosciences EV to EBITDA ratio is -1.78, with an EV/FCF ratio of -2.37.
EV to Sales0.00
EV to EBITDA-1.78
EV to Free Cash Flow-2.37
EV to Operating Cash Flow-2.37
Balance Sheet
Cogent Biosciences has $287.08M in cash and marketable securities with $17.47M in debt, giving a net cash position of -$269.61M billion.
Cash & Marketable Securities$287.08M
Total Debt$17.47M
Net Cash-$269.61M
Net Cash Per Share-$2.37
Tangible Book Value Per Share$3.49
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cogent Biosciences is $16.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.67
Price Target Upside314.68%
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast
EPS Growth Forecast-2.53%